

## VOLUME 37 1990

### SUBJECT INDEX

- Acetylcholine, 155, 213, 597  
 Acetylcholinesterase, 439  
 $\alpha_1$ -Acid glycoprotein, AGP, 485  
 Acquisition, 405  
 Active avoidance, 295  
 Adenosine, 107  
 Adenosine analogs, 747  
 Adenosine A<sub>1</sub> receptor, 747  
 Adenosine A<sub>2a</sub> receptor, 747  
 Adenosine receptors, 107  
 Adenylate cyclase, 417  
 Adrenal medulla, 135  
 Adrenalectomy, 399, 703  
 Adrenodemedullation, 399  
 Affect, 425  
 Affective disorders, 213  
 Aggression, 101, 493  
 Aggressive behavior, 433  
 Agonist/antagonists, 193  
 Agonist sensitivity, 627  
 Alcohol, 17, 29, 359  
 Alpha<sub>2</sub>-receptors, 675  
 Alprazolam, 177, 365  
 (–)Alprenolol, 83  
 Alzheimer's disease, 405, 799  
 D-Amino acids, 593  
 Amnesia, 47, 53, 295  
 Amphetamine, 259, 303, 417, 451  
*d*-Amphetamine, 349, 493  
 Amygdala, 439  
 Analeptic, 375  
 Analgesia, 123, 193, 497, 661, 713  
 Angiotensin I, 831  
 Angiotensin II, 831  
 Angiotensin converting enzyme, 831  
 Anisomycin, 295  
 Anorexia, 201  
 Antagonism, 505  
 Anticholinesterase, 267  
 Antidepressant, 167, 247  
 Antipanic agents, 167, 177  
 Antipsychotic, 235  
 Anxiety, 167, 177  
 Anxiolytic, 235, 335  
 Apomorphine, 89, 231, 253, 451, 471, 755  
 Apropen, 117  
 Arecoline, 213  
 Asymmetric dissociation, 47  
 Atropine, 117  
 Atypical neuroleptic obesity, 227  
 Autogrooming, 63  
 Autoimmune disease, 527  
 Aversion, 311, 689  
 Aversive behavior, 785  
 Aversive response, 779  
 Avoidance, 843  
 Avoidance acquisition, 655  
 Avoidance behavior, 571  
  
 Bar press, 339  
 Bar pressing, 187  
 Barbiturate, 343  
 Baroreceptor reflex, 821  
 Barrel rotation, 523  
 Behavior, 11, 71, 135, 289, 349, 627, 649, 717, 831  
 Behavior genetics, 795  
 Behavioral indices, 567  
 Benzodiazepine, 587  
 Benzodiazepine receptors, 365  
 Bestatin, 779  
 Beta receptor subsensitivity, 567  
 Beta-1 vs. beta-2 specificity, 567  
 Bicuculline, 667  
 Biological marker, 485  
 Bipolar affective illness, 417  
 Blood and brain ethanol, 577  
 Blood pressure, 325  
 BMY 7378, 283, 335  
 Body composition, 393  
 Body temperature, 773  
 Body weight, 17, 379, 393  
 Bombesin, 689  
 Brain catecholamines, 639  
 Brain monoamines, 259  
 Brain regions, 461  
 Bromopride, 571  
 $\alpha$ -Bungarotoxin binding sites, 239  
 Buprenorphine, 193, 247  
 Bupropion, 167, 247  
 Burying behavior, 77  
 Buspirone, 235, 335, 451  
 Butorphanol, 193, 511  
 [<sup>35</sup>S] *t*-Butylbicyclophosphorothionate binding, 433  
  
 Caffeine, 349  
 Calcium, 457  
 Calcium channels, 253  
 Cannabidiol, 299  
 Cannabinol, 299  
 Capsaicinized chow, 649  
 Captopril, 779, 831  
 Carbamazepine, 551  
 Carbohydrate, 207, 735  
 Carbohydrate intake, 461  
 Carboxyhemoglobin, 17, 29  
 Castration, 471  
 Cat, 1, 283  
 Catecholamines, 259  
 CCK-A receptor, 523  
 Ceruletide, 523  
 CGS 9896, 235  
 Chemical stimulation, 411  
 Chlordiazepoxide, 101, 177, 235, 311  
 Chlorpromazine, 235  
 Choline deprivation, 799  
 Cholinergic, 117, 213, 375  
 Cholinergic function, 811  
 Cholinesterase, 161  
 Chow, 649  
 Chronic cannulae, 411  
 Chronic stress, 675  
 Chronic treatment, 567  
 Cigarette yield, 17, 29  
 Circadian rhythms, 239  
 Circling, 387  
 Classical conditioning, 231  
 Clonidine, 167, 821  
 CNS depression, 795  
  
 Cocaine, 161, 339, 349, 359, 371, 375, 551, 643, 693, 707, 761, 773, 795  
 Cocaine N-demethylase, 161  
 Coffee, 17, 29  
 Cognitive tasks, 561  
 Cold tolerance, 107  
 Colliculus superior, deeper layers, 1  
 Conditioned avoidance, 639  
 Conditioned place preference, 425, 633, 383  
 Conditioned taste aversion, 59, 497, 693  
 Conflict behavior, 167, 177  
 $\omega$ -Conotoxin, 253  
 Consistency, 697  
 Controllability, 613  
 Convulsions, 577  
 Copulation, 471  
 Cortex, 135  
 Cortical stroke, 679  
 Corticosterone, 613  
 pCPA, 83, 283  
 Cyclohexylamine, 445  
 Cyclophosphamide, 527  
 Cytisine, 113  
  
 D1 receptor, 289, 317, 627  
 D2 receptor, 227, 289, 317, 371, 627  
 DA receptors (presynaptic), 675  
 Day-old chicks, 729  
 Delay of reinforcement, 643  
 Delta-9-tetrahydrocannabinol, 349  
 Demeclocycline, 417  
 Dependence, 59, 343  
 Depression, 213  
 Desipramine, 167, 277  
 Development, 129, 161  
 Developmental trends, 811  
 Diazepam, 77, 451, 505  
 Diet selection, 207, 461  
 Differential reinforcement of response duration schedule, 607  
 DiMe-C7, 329, 839  
 Discrimination, 843  
 Diurnal cycle, 201  
 DMI, 675  
 Dog, 607  
 DOI, 825  
 DOM, 769  
 Dominance rank, 493  
 L-Dopa, 259  
 DOPAC, 571  
 Dopamine, 89, 113, 135, 149, 227, 277, 289, 317, 329, 465, 471, 539, 607, 627, 639  
 Dopamine receptors, 387  
 Dorsal noradrenergic bundle, 597  
 Doxepin, 247  
 DPDPE, 193  
 Drinking, 531  
 Drinking behavior, 527  
 Drug discrimination, 289, 511, 623, 769  
 Drug interactions, 349  
 Drug withdrawal, 785  
 Drugs of abuse, 425, 633  
 Dystonia, 129

Ear-scratch, 95  
 EEG, 761  
 EEG arousal, 375  
 Effect-addition, 349  
 Efficiency of food utilization, 393  
 Electrical brain stimulation, 311  
 Emesis, 283  
 Endogenous opioids, 193  
 Endogenous serotonin uptake modulator, 485  
 Endogenous state dependency, 47  
 $\beta$ -Endorphin, 47, 661  
 Enhancement of retrieval, 47  
 [Leu]Enkephalin, 655  
 Enkephalin metabolites, 655  
 Enkephalins, 593  
 Estrous cycle phase differences, 77  
 Ethanol, 205, 359, 379, 747  
 Ethanol intake, 633  
 Ethanol intoxication, 577  
 Ether, 399  
 Ethylketocyclazocine, 193, 713  
 Excitatory amino acids, 843  
 Excitotoxin lesions, 755  
 Experimental model, 811  
 Exploratory activity, 743  
 Exploratory behavior, 445  
  
 F344 rats, 795  
 FAD-monooxygenase, 161  
 False cholinergic transmitter, 799  
 False precursor (NADe), 811  
 False transmitter, 811  
 Fasciculin, 439  
 Fat, 207, 317  
 Feeding, 201, 207, 317, 497, 531  
 Feeding behavior, 735  
 Fenfluramine, 219, 623  
 Fentanyl, 193  
 FG 7142, 311  
 Fixed interval schedule, 339  
 Flesinoxan, 335  
 Flumazenil, 505  
*cis*-Flupenthixol, 387  
 Food intake, 207, 393, 461  
 Foot-shock, 303  
 Formalin test, 713  
 $\beta$ -Funaltrexamine, 713  
  
 GABA, 329  
 GABA<sub>A</sub> receptor, 343  
 Ganglioside, 679  
 Gender differences, 77  
 Genetic, 831  
 Genetic mouse lines, 593  
 Gepirone, 451  
 Glucose and saccharin, 551  
 Glucose incorporation, 393  
 Glycemia, 399  
 Glycerol renal failure, 583  
 GM1, 679  
 Grooming, 689  
  
 Haloperidol, 451, 607  
 Hamster, 383  
 Heart rate, 325  
 Hedonics, 317  
 Hepatotoxicity, 161  
 Hippocampus, 149, 375  
 5-HIAA, 461  
 Holeboard, 273  
 HPLC of cholinergic compounds, 799  
 5-HT, 461  
 5-HT<sub>1A</sub>, 769  
 5-HT<sub>2</sub>, 769  
 5-HT<sub>1</sub> agonist, 83  
 5-HT<sub>1A</sub> agonists, 335  
 5-HT<sub>1A</sub>-receptor, 95  
 5-HT<sub>1B</sub>-receptor, 95  
 5-HT<sub>2</sub>-receptor, 95  
 5-HT turnover, 461  
 6-Hydroxydopamine, 231, 329, 755  
 Human performance, 561  
 Human subjects, 511  
 HVA, 571  
 Hydromorphone, 511  
 Hyperbaric environment, 577  
 Hyperthermia, 761  
 Hypobaric hypoxia, 53  
 Hypothalamus, 299  
 Hypothermia, 343, 649  
 Hypothyroidism, 627  
 Hypovolemia, 821  
  
 Imipramine, 567  
 Immunoassay, 485  
 Indorenate, 83  
 Inescapable shock, 539  
 Inhibitor, 831  
 Interaction, 95, 405, 761  
 Intermediate memory, 729  
 Intracerebroventricular, 193, 329, 747  
 Intracranial cannula, 411  
 Intracranial injection, 743  
 Intracranial self-stimulation, 187  
 Intrathecal injection, 779  
 Intravenous, 551  
 Ipsapirone, 335  
 Ischemia, 679  
  
 Kainic acid, 71, 755  
 Ketamine, 667  
 Ketanserin, 129  
 Ketotifen analogues, 785  
 Kindling, 685, 761  
 Kynurenic acid, 843  
 Kynurenine, 71  
  
 Lab-field comparison, 697  
 Lateral hypothalamic area, 393  
 Lateral hypothalamus, 227  
 LD<sub>50</sub>, 205  
 Learning, 679  
 Learning and memory, 41  
 Lethality, 267  
 D-Leucine, 593  
 LHRH, 639  
 Ligand binding, 717  
 Limbic system, 149  
 Lithium, 417  
 Locomotion, 113  
 Locomotor activity, 89, 135, 149, 239, 259, 303, 329, 339, 743, 795  
 Low doses, 607  
 Luteinizing hormone, 299  
  
 Macronutrient, 207, 735  
 Male and female rats, 693  
 Marijuana, 561  
 Marmoset, 717  
 Masculine sexual behavior, 83  
 MDMA, 633  
 Mecamylamine, 405  
 Medial hypothalamus, 735  
 Medial preoptic area, 471  
 Median raphe nucleus, 329  
 Memory, 155, 295, 439, 597, 679  
 Memory consolidation, 729  
 Memory files, 47  
 Memory modulation, 655  
 Meperidine, 193  
 Mesencephalic locomotor region, 311  
 Mesolimbic dopamine system, 303  
 Mesulergine, 283  
 Metabolic control, 393  
 Metergoline, 283  
 Methadone, 247  
 Methemoglobin, 457  
 Methylenedioxymethamphetamine, 633  
 Mianserin, 167  
 Mice, 101, 161, 273, 505  
 Microdialysis, 227  
 Microinfusion, 411  
 Microinjection, 411  
 Midazolam, 335  
 Minocycline, 417  
 MK-329, 523  
 MK-801, 41, 101  
 Morphine, 59, 207, 303, 349, 383, 425, 505, 531, 689, 713  
 Morphine analgesia, 703  
 Morphine content, 703  
 Motor behavior, 1  
 Motor coordination, 83  
 Motor incoordination, 747  
 Mouse, 655, 717, 785  
 Mrl lpr/lpr mice, 527  
 Mu, kappa and delta opioid receptors, 193  
 Multiple cannulae, 411  
 Muscarinic, 213, 811  
 Muscarinic receptor binding, 439  
 Muscimol, 329  
  
 Nalbuphine, 193, 511  
 Nalmefene, 497  
 Naloxone, 383, 425, 511, 531, 593  
 Naltrexone, 425, 497  
 NBR rats, 795  
 $\alpha$ -Neoendorphin, 661  
 Neural transplants, 135  
 Neurokinin A, 779  
 Neuroleptics, 465, 607  
 Neuronal plasticity, 685  
 Nicergoline, 53  
 Nicotine, 11, 59, 113, 239, 743  
 Nicotine tolerance, 743  
 Nicotinic receptors, 239  
 Nimodipine, 457  
 Nipple attachment, 219  
 NMDA, 685  
 Nonsmokers, 11  
 Noradrenaline, 539, 597, 729  
 Norepinephrine, 299, 639  
 Norethisterone, 477  
 19-Nor steroids, 477  
 Nose poke, 339  
 Novelty, 89  
 Nucleus accumbens, 113, 149, 303, 329, 743  
 Nucleus basalis magnocellularis, 597  
 Nucleus subcoeruleus, 187  
 Nucleus tractus solitarius, 821  
  
 8-OH-DPAT, 769  
 5-OMe DMT, 769  
 Ontogenesis, 667  
 Open-field behavior, 213

- Operant behavior, 117, 465  
 Opioid, 207, 247, 425, 511, 593  
 Opioid antagonist, 497  
 Opioid binding, 505  
 Oxytocin, 63, 253
- Pain, 689  
 Palatability, 451  
 Panic disorder, 167, 177  
 Paraventricular nucleus, 201, 735  
 Parietal, 679  
 Passive avoidance, 405  
 Pavlovian conditioning, 205  
 Penile erection, 253  
 Pentazocine, 193  
 Performance, 11, 643  
 Periaqueductal gray, 311  
 Perinatal treatment, 571  
 Perinatal undernutrition, 675  
 Perseveration, 679  
 Phenobarbital, 177  
 D-Phenylalanine, 593  
 Phenylpropanolamine, 201  
 Phospholipids, 799  
 Phosphoramidon, 779  
 Physiological effects, 561  
 Physostigmine, 117, 155, 187  
 Picrotoxin, 667  
 Pigeons, 247, 349  
 Pimozide, 465  
 (–)Pindolol, 83  
 Pituitary, 299  
 Pizotifen, 461  
 Place-preference, 89, 383, 689  
 Plasma catecholamines, 359  
 Plasma cotinine, 17, 29  
 Plasma free fatty acids, 393  
 Plasma glucose, 393  
 Plasma insulin, 393  
 Plasma nicotine, 17, 29  
 Plasma THC levels, 561  
 Porsolt's swim test, 273  
 Positive affect, 633  
 Positive reinforcement, 317, 425  
 Postsynaptic receptors, 283  
 Power-spectra (FFT), 761  
 Prednisolone, 703  
 Prefrontal cortex, 685  
 Prenatal, 371  
 Preparedness, 613  
 Pressure reversal, 577  
 Presynaptic DA2 receptors, 607  
 Primary polydipsia, 831  
 Profadol, 193  
 Progesterone, 433  
 Progestin metabolism, 477  
 Progestins, 477  
 Progressive degenerative dementia, 811  
 Prolactin, 571  
 Propranolol, 283  
 Protein, 207, 735  
 Protein intake, 461  
 Psychomotor stimulant, 339  
 Psychomotor tasks, 561  
 Puffing topography, 29  
 Punished responding, 335  
 Putrescine, 445  
 Pyridostigmine, 267
- Quantitative autoradiography, 433  
 Quinpirole, 289, 387  
 Quipazine, 129, 219
- Radioligand binding, 557  
 Rat, 41, 71, 117, 123, 187, 227, 235, 253, 289, 311, 379, 471, 531, 539, 551, 577, 597, 623, 627, 643, 667, 689, 717, 761, 785, 843  
 Rat brain cortex, 445  
 Rat brain membranes, 365  
 Rat strains, 339  
 Reactivity, 697  
 Receptor binding, 365, 497  
 Receptors, 213  
 Reference memory, 587  
 Regression, 1  
 Residual effects, 561  
 Restraint stress, 193  
 Retention, 405  
 Reversal learning, 155  
 Reward, 317, 425, 465, 685  
 Ring-methyl amphetamine analogs, 835  
 Ro15-1788, 177  
 Rotation behavior, 231, 755  
 RU 24969, 335  
 Runway, 531
- Schedule-controlled behavior, 339  
 Scopolamine, 117, 405, 587, 597  
 Scratching, 689  
 Seizure, 343, 583, 667, 761  
 Self-administration, 551, 707  
 Self-stimulation reward, 277  
 Sensitization, 303, 707, 761  
 Sensory, perceptual, and cognitive behaviors, 811  
 Serial discrimination, 155  
 Serotonergic anxiolytics, 77  
 Serotonin, 129, 219, 539, 623, 735, 769, 825  
 Serotonin receptors, 283  
 Serotonin syndrome, 83  
 Serum estradiol, 325  
 Serum testosterone, 325  
 Sex differences, 325, 539  
 Sexual behavior, 63, 477, 825  
 Sham feeding, 317  
 Sigma receptor, 557  
 Single tube procedure, 693  
 SKF 38393, 289, 387  
 SM 3997, 335  
 Smokers, 11  
 Smoking history, 17, 29  
 SMS 201-995, 523  
 Social interactions, 63  
 Sodium nitrite, 457  
 Soman, 267  
 Somatostatin, 523  
 Spatial learning, 405, 587  
 Spinalization, 505  
 Spontaneously hypertensive rats, 773  
 Squirrel monkeys, 335  
 Steroids, 123  
 Stimulus properties, 835  
 Stimulus properties of drugs, 623  
 Stress, 213, 273, 359, 399, 661, 773  
 Stressor, 613  
 Stress-related hormones, 729
- Stress response, 485  
 Striatum, 135, 371, 755  
 Stroke, 679  
 Stumptail macaques, 493  
 Subjective effects, 561  
 Substance P, 329, 779, 839  
 Substantia nigra, 135  
 Substantia nigra lesions, 231  
 Sulpiride, 227, 607  
 Supersensitivity, 623, 755  
 Suprachiasmatic nucleus, 735  
 Switch-off test, 311
- Tail-flick, 661  
 Tail-flick assay, 193  
 Taste, 317  
 Taste aversion, 551  
 Taste aversion learning, 379  
 Taste reactivity, 451  
 Tegretol, 551  
 Temporal regulation, 607  
 Testosterone, 299, 471  
 Tetrahydrocannabinol, 299  
 Theophylline neurotoxicity, 583  
 Thermogenesis, 107  
 Thiocyanate, 17, 29  
 Three-session paradigm, 47  
 Thyroid hormones, 627  
 Tiflucarbine, 769  
 Timeout from avoidance, 235  
 Tolerance, 205, 239, 343  
 Toxicity, 497  
 Trazodone, 167  
 Tremor, 129  
 Triazolobenzodiazepines, 365  
 Tryptophan, 273  
 Two-tube choice procedure, 693  
 Tyrosine, 259
- U50,488, 713  
 U50,488H, 193, 531  
 Urinary catecholamines and cortisol, 697
- Vasopressin, 821  
 Ventral tegmental area, 329, 839  
 Verapamil, 457  
 Vigilance, 643  
 Viloxazine, 567  
 Vinburnine, 53  
 Vincamine, 53  
 Voles, 63  
 Voluntary consumption, 359
- Water maze acquisition, 41  
 Water reinforcement, 465  
 Weakly reinforced training, 729  
 Weanling rats, 219  
 Wet dog shakes, 825  
 White-dark preference, 445  
 Withdrawal, 59  
 Working memory, 587  
 WY 47,846, 335
- Xylamide, 219
- Yawning, 253
- R(+) and S(–)-Zacopride, 717

## AUTHOR INDEX

- Aaltonen, M., 405  
 Abbott, F. V., 713  
 Ader, R., 527  
 Agmo, A., 83  
 Ahlenius, S., 843  
 Ali, S. F., 371  
 Allen, J. T., 497  
 Angst, M. J., 311  
 Anisman, H., 613  
 Arezo, S., 59  
 Argiolas, A., 253  
 Arnold, F. J., 485  
 Asencio, M., 551  
 Awad, A., 393
- Baker, M. L., 343  
 Baptista, T., 227  
 Bardo, M. T., 89  
 Barnes, J. M., 717, 839  
 Barnes, N. M., 717, 785, 839  
 Barrett, J. E., 335  
 Bartke, A., 299  
 Bateman, S. T., 219  
 Battaglia, G., 557  
 Bättig, K., 743  
 Becker, C. A., 167  
 Bellinger, L. L., 393  
 Belmaker, R. H., 417  
 Beninger, R. J., 387  
 Benloucif, S., 295  
 Bennett, E. L., 295  
 Berge, O.-G., 577  
 Bernardis, L. L., 393  
 Berridge, K. C., 451  
 Berz, S., 743  
 Beyer, C., 123  
 Bigelow, G. E., 511  
 Bilsky, E. J., 425, 633  
 Boer, G., 539  
 Booth, R. A., 799, 811  
 Bridges, R. B., 17, 29  
 Brostrom, P. A., 497  
 Brown, J. W., 259  
 Bruhwlyer, J., 607  
 Bydlowski, C. R., 639  
 Byrd, L. D., 493
- Caba, M., 123  
 Calcagnetti, D. J., 193  
 Cameron, D. L., 627  
 Cannon, D. S., 379  
 Canonaco, M., 433  
 Carino, M. A., 375  
 Carroll, M. E., 551  
 Carter, C. S., 63  
 Chleide, E., 607  
 Cleary, J., 247  
 Clissold, D. B., 155  
 Cohen, N., 527  
 Combs, J. G., 17, 29  
 Commissaris, R. L., 167, 177  
 Cone, E. J., 561  
 Cools, A. R., 1  
 Corbett, D., 685  
 Costall, B., 717, 785, 839  
 Couvaris, M. K., 461  
 Cox, A. J., 839  
 Cramer, C. P., 219  
 Crocker, A. D., 627
- Crowe, S. F., 729
- D'Agata, V., 53  
 Dajas, F., 439  
 Dalmaz, C., 439  
 Dar, M. Saeed, 747  
 Darmani, N. A., 95  
 Davies, B. T., 201  
 Debski, T. D., 11  
 DeHaven-Hudkins, D. L., 497  
 Depoortere, R., 311  
 De Vry, J., 769  
 Dias, M., 439  
 Dib, B., 649  
 Dickson, P. R., 387  
 Dilsaver, S. C., 213  
 Di Scala, G., 311  
 Dolnikoff, M. S., 399  
 Domeney, A. M., 717, 839  
 Drago, F., 53  
 Durcan, M. J., 273
- Edwardson, J. A., 597  
 Elliott, P. J., 329  
 Ellis, D. M., 167, 177  
 Elsmore, T. F., 117  
 Emerich, D. F., 149  
 Epstein, L. H., 11  
 Ericson, E., 843  
 Escalante, A., 83  
 Eterović, V. A., 445  
 Ettenberg, A., 465  
 Evans, E. B., 349
- Fahey, J. M., 457  
 Feenstra, M. G. P., 539  
 Felicio, L. F., 571, 639  
 Ferchmin, P. A., 445  
 Ferkany, J. W., 497  
 Fernández-Guasti, A., 77, 83  
 File, S. E., 587  
 Fleetwood, S. W., 193  
 Flint Beal, M., 71  
 Fontana, D. J., 167, 177  
 Frambes, N. A., 371  
 Frankenhaeuser, M., 325, 697  
 Fredrikson, M., 697  
 Freeman, G. B., 259  
 Friedland, J., 831
- Galanopoulou, P., 461  
 Galizio, M., 235  
 García, G. A., 477  
 Garcia-Cabrera, I., 577  
 Garner, L. L., 239  
 Genovese, R. F., 117  
 George, F. R., 795  
 Gessa, G. L., 253  
 Giannacopoulos, G., 461  
 Gibbs, J., 317  
 Gibbs, M. E., 729  
 Giordano, M., 135  
 Glaser, T., 769  
 Gleeson, S., 335  
 Glennon, R. A., 95, 557, 769, 835  
 Goldberg, S. R., 339  
 Gorzalka, B. B., 411, 825  
 Gosnell, B. A., 207
- Grassi, M., 53  
 Graziani, M., 531  
 Greenberg, D., 317  
 Grilly, D. M., 643  
 Grota, L. J., 527
- Haley, N. J., 17, 29  
 Halikas, J. A., 551  
 Hall, F. S., 277  
 Hamburger, R., 417  
 Harris, N., 359  
 Hartgraves, S. L., 267  
 Heinsbroek, R. P. W., 539  
 Heise, G. A., 155  
 Heishman, S. J., 561  
 Henningfield, J. E., 561  
 Hernandez, L., 227  
 Higgs, R. A., 835  
 Hilakivi-Clarke, L. A., 273  
 Hildebrand, J. P., 755  
 Hill, T. J., 167  
 Ho, I. K., 343, 773  
 Hoebel, B. G., 227  
 Hoh, J., 213  
 Hole, K., 505  
 Holtzman, S. G., 193  
 Hong, E., 83  
 Horger, B. A., 707  
 Horita, A., 375  
 Horvitz, J. C., 465  
 Hoskins, B., 773  
 Huang, C., 439  
 Hubbell, C. L., 633  
 Huestis, M. A., 561  
 Hughes, C. E., 693  
 Hui, Y., 633  
 Hull, E. M., 471  
 Humble, J. W., 17, 29  
 Hume, A. S., 343
- Ieni, J. R., 259  
 Imura, H., 523  
 Iovino, M., 821  
 Isaacson, R. L., 457  
 Ishikawa, Y., 523  
 Ishizuka, Y., 773  
 Ito, Y., 343  
 Izquierdo, I., 439
- Jacob, R. G., 11  
 Jacobson, K. A., 107  
 Jaeckle, R. S., 213  
 James, J. R., 59  
 Janak, P. H., 655  
 Jaspers, R. M. A., 1  
 Jenden, D. J., 799, 811  
 Johnson, D. N., 717  
 Journey, J. W., 235
- Kaplita, P. V., 497  
 Karpiak, S. E., 679  
 Kawamura, H., 187  
 Keith, A. B., 597  
 Keller, E. A., 675  
 Kelley, A. E., 277  
 Kelly, M. E., 717, 785, 839  
 Kerényi, S. Z., 267  
 Kerwin, J. M., 597  
 Kimchi, O., 417
- Kisara, K., 779  
 Kishioka, S., 703  
 Kitabata, Y., 703  
 Klein, E., 417  
 Knusel, B., 799  
 Kofman, O., 417  
 Kolmonpunporm, M., 755  
 Komisaruk, B. R., 123  
 Kragh, R., 551  
 Krahn, D. D., 207
- Lac, S. T., 551  
 Lacy, M., 89  
 Lasoñ, W., 661  
 Laurentz, S. D., 799, 811  
 Lauria, N., 53  
 Lavoisy, J., 567  
 Lee, T. F., 107  
 Leeka, J. K., 379  
 Lehman, M. N., 755  
 Leibman, D., 161  
 Leibowitz, S. F., 735  
 Lemus, A. E., 477  
 Lenègre, A., 567  
 Lesko, L. J., 497  
 Leyton, M., 303  
 Li, D. J., 107  
 Lichtman, A. H., 219  
 Liebson, I. A., 511  
 Lindstedt, G., 325  
 Linnoila, M., 273  
 Lister, R. G., 273  
 Livezey, G. T., 761  
 Lloyd, S., 597  
 Lorden, J. F., 129  
 Lorens, S. A., 329, 689  
 Lu, S. Y., 135  
 Lucot, J. B., 283  
 Lundberg, U., 325, 697
- McAllister, K. H., 101  
 McCabe, R. T., 365  
 McCarthy, M. M., 123  
 McCloskey, T. C., 177  
 McLamb, R. L., 41
- Mahan, D. R., 365  
 Mabbutt, P. S., 587  
 MacDonald, J. S., 679  
 Macenski, M. J., 247  
 Maggi, A., 433  
 Majchrzak, M. J., 207  
 Maltchik, M., 47  
 Mareš, P., 667  
 Marglin, S. H., 425  
 Martin, B. R., 95  
 Martin, S. P., 493  
 Martinez, J. E., Jr., 655  
 Mattingly, B. A., 89  
 Mavunkel, B. J., 497  
 Medina, J. H., 439  
 Meisenberg, G., 689  
 Melchior, C. L., 205  
 Melin, B., 697  
 Melis, M. R., 253  
 Mercier, M., 607  
 Meyerson, L. R., 485  
 Michela, V. L., 129  
 Miguel, S., 567

- Miller, S. H., 213  
 Mitsushio, H., 329  
 Miyamoto, Y., 703  
 Molina, V. A., 675  
 Moody, C. A., 755  
 Morali, G., 477  
 Morita, N., 703  
 Morley, B. J., 239  
 Morrell, J., 383  
 Mortimer, R. B., 295  
 Moynihan, J. A., 527  
 Munson, H. R., 717  
 Murakami, Y., 523  
 Murphy, L. L., 299  
 Murphy, M. R., 267  
 Museo, E., 113  
 Musgrave, M. A., 387  
  
 Nanry, K. P., 41  
 Nasello, A. G., 571, 639  
 Naylor, R. J., 717, 785, 839  
 Nencini, P., 531  
 Netto, C. A., 47, 439  
 Newman, M., 417  
 Ng, K. T., 729  
 Nir, T., 417  
 Nocjar, C., 643  
 Norman, A. B., 135, 755  
 Nunes, M., 47  
  
 Oller Do Nascimento Curi,  
 C. M., 399  
 Onaivi, E. S., 785  
 Oropeza, M. V., 477  
 Orsingher, O. A., 675  
 Ortiz, A., 679  
 Ozaki, M., 703  
  
 Pandey, U., 95  
 Panocka, I., 593  
 Paris, J. M., 329  
 Peck, J. A., 213  
 Pérez-Palacios, G., 477  
 Perkins, K. A., 11  
  
 Perry, E. K., 597  
 Picazo, O., 77  
 Porsolt, R. D., 567  
 Preston, K. L., 511  
 Prince, C. R., 613  
 Przewlocka, B., 661  
  
 Quillfeldt, J., 439  
  
 Ramzan, I., 583  
 Raskovsky, S., 439  
 Rehm, S. R., 17, 29  
 Reid, L. D., 425, 633  
 Ribeiro, E. B., 399  
 Rice, K. M., 799, 811  
 Riekkinen, P., 405  
 Riekkinen, P., Jr., 405  
 Roch, M., 799, 811  
 Rockhold, R. W., 773  
 Rokyta, R., 667  
 Rosecrans, J. A., 59  
 Rosenzweig, M. R., 295  
 Rosland, J. H., 505  
 Royal, S. A., 235  
 Russell, R. W., 811  
 Rzeszotarski, W. J., 497  
  
 Sadowski, B., 593  
 Sahgal, A., 597  
 Saitoh, Y., 187  
 Sakurada, S., 779  
 Sakurada, T., 779  
 Sanberg, P. R., 135, 755  
 Sandner, G., 311  
 Saunders, P. A., 343  
 Scaletta, L. L., 471  
 Scalzo, F. M., 371  
 Schechter, M. D., 623  
 Schefke, D. M., 167  
 Scheider, F., 439  
 Schenk, S., 707  
 Schnur, P., 383  
 Schulze, H. G., 411  
 Sexton, J. E., 11  
  
 Shelton, K., 707  
 Shimatsu, A., 523  
 Shimon, H., 417  
 Shipley, M. T., 135  
 Silveira, R., 439  
 Silverman, P. B., 231  
 Silverstein, E., 831  
 Simmons, W. H., 689  
 Sirviö, J., 405  
 Smith, E. O., 493  
 Smith, G. P., 317  
 Smith, J. D., 557  
 Smith, M. S., 299  
 Smith, R. B., 365  
 Smolen, A., 161  
 Smolen, T. N., 161  
 Soblosky, J. S., 259  
 Spadaro, F., 53  
 Sparber, S. B., 761  
 Spear, L. P., 371  
 Spencer, D. G., Jr., 769  
 Stancampiano, R., 253  
 Steardo, L., 821  
 Steger, R. W., 299  
 Stellar, J. R., 277  
 Steranka, L. R., 497  
 Stewart, J., 303  
 Stiller, R. L., 11  
 Stratton, S. E., 129  
 Suh, J. S., 735  
 Sumová, A., 661  
 Svensson, T. H., 843  
  
 Tan-No, K., 779  
 Taylor, J., 359  
 Theophanopoulos, C., 461  
 Thompson, T., 247  
 Thurmond, J. B., 259  
 Tilson, H. A., 41  
 Toth, E., 587  
 Traumata, D., 213  
 Treit, D., 451  
 Tuomisto, M., 697  
 Turbek, J. A., 17, 29  
  
 Valenti, A., 433  
 Valerio, C., 53  
 van de Poll, N. E., 539  
 van Galen, H., 539  
 van Haaren, F., 539, 693  
 Vanacore, A., 821  
 Varonos, D., 461  
 Vécsei, L., 71  
 Velíšek, L., 667  
 Velíšková, J., 667  
 Villanueva, H. F., 59  
 Vogel, W. H., 359  
  
 Waite, J. J., 799  
 Wakade, C. G., 679  
 Wallin, L., 325  
 Walsh, T. J., 149  
 Walton, D. M., 63  
 Wamsley, J. K., 365  
 Wang, L. C. H., 107  
 Watson, N. V., 825  
 Weatherford, S. C., 317  
 Weiss, G. F., 735  
 Welker, J. A., 235  
 Wellman, P. J., 201  
 Welzl, H., 743  
 Wenger, G. R., 349  
 Williams, J. E. G., 289  
 Williams, L. R., 41  
 Wilson, W. A., 41  
 Wise, R. A., 113  
 Witkin, J. M., 117, 339  
 Witt, D. M., 63  
 Woolverton, W. L., 289  
 Wyatt, L. M., 755  
  
 Yabase, M., 375  
 Yamada, T., 779  
 Yamamoto, H., 703  
 Yamanishi, T., 703  
 Young, R., 717  
  
 Zaia, C. T. B. V., 399